Healthcare Most Active Stocks: MannKind Corporation (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Amicus Therapeutics (NASDAQ:FOLD), Geron Corporation (NASDAQ:GERN), Gilead Sciences (NASDAQ:GILD)

MannKind Corporation (NASDAQ:MNKD) VP David Thomson sold 30,000 shares of the stock on the open market in a transaction that occurred on Thursday, June 26th. The shares were sold at an average price of $10.51, for a total transaction of $315,300.00. Following the transaction, the vice president now directly owns 102,286 shares in the company, valued at approximately $1,075,026. MannKind Corporation (NASDAQ:MNKD) stock performance was … Continue reading Healthcare Most Active Stocks: MannKind Corporation (NASDAQ:MNKD), Pfizer Inc. (NYSE:PFE), Amicus Therapeutics (NASDAQ:FOLD), Geron Corporation (NASDAQ:GERN), Gilead Sciences (NASDAQ:GILD)

Hot Biotech Movers: Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), Insmed Incorporated (NASDAQ:INSM), Gilead Sciences, Inc. (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) saw a significant decrease in short interest during the month of May. As of May 30th, there was short interest totalling 8,284,614 shares, a decrease of 15.5% from the May 15th total of 9,799,100 shares. Several analysts have recently commented on the stock. Analysts at Roth Capital downgraded shares of Chelsea Therapeutics International from a “buy” rating to a “neutral” … Continue reading Hot Biotech Movers: Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), Insmed Incorporated (NASDAQ:INSM), Gilead Sciences, Inc. (NASDAQ:GILD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Geron Corporation (NASDAQ:GERN) on June 12 announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST). The partial clinical hold was placed in March 2014 due to a safety signal of hepatotoxicity that was identified in clinical trials of imetelstat. Geron Corporation (NASDAQ:GERN) stock performance was 4.01% in last … Continue reading Biotech Movers: Geron Corporation (NASDAQ:GERN), Idenix Pharmaceuticals Inc (NASDAQ:IDIX), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Gilead Sciences (NASDAQ:GILD)

Apple Inc. (NASDAQ:AAPL)’s resurgent stock may have as much to do with financial engineering as the company’s technological wizardry. Monday marked Apple Inc. (NASDAQ:AAPL)’s first stock split in nine years, a move designed to make it more affordable to buy shares of the iPhone and iPad maker. Apple Inc. (NASDAQ:AAPL) stock performance was 1.60% in last session and finished the day at $93.70. Traded volume … Continue reading Hot Watch List: Apple Inc. (NASDAQ:AAPL), Twitter Inc (NYSE:TWTR), Gilead Sciences, Inc. (NASDAQ:GILD), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

AstraZeneca Plc (ADR) (NYSE:AZN), in the headlines for spurning buyout offers from Pfizer Inc, aims to regain prominence in oncology with compelling trial results and a splashy exhibit booth at the world’s largest meeting of cancer doctors. AstraZeneca plc (ADR) (NYSE:AZN) stock performance was -0.83% in last session and finished the day at $72.76. Traded volume was 5.14million shares in the last session and the … Continue reading Healthcare Active Stocks: AstraZeneca plc (ADR) (NYSE:AZN), NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD)

Johnson & Johnson (NYSE: JNJ) has inked a global licensing deal with the privately held Aduro BioTech for developing new therapies to treat prostate cancer. According to the oncology deal, the private company granted Janssen Biotech, a division of Johnson & Johnson, the exclusive license to certain candidates specifically engineered for the treatment of prostate cancer on the basis of Aduro’s proprietary live-attenuated double-deleted (LADD) … Continue reading Healthcare Active Stocks: Johnson & Johnson (NYSE:JNJ), Endo International (NASDAQ:ENDP), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY)